Insights

Growing Clinical Pipeline Salubris Bio has recently advanced its innovative antibody fusion protein JK07 for heart failure into Phase 1b trials, indicating a focus on cardiovascular therapeutics with significant market potential, providing opportunities to collaborate on clinical development and commercialization.

Strategic Funding & Expansion The company secured $32 million in financing from Shenzhen Salubris Pharmaceuticals, demonstrating strong backing and growth ambitions, making it an attractive partner for joint ventures and co-development of high-value biologics.

Collaborative Research Focus With close integration with its parent company and over 150 research scientists, Salubris Bio is positioned to leverage extensive R&D resources for novel biologic therapeutics, offering partnerships in early-stage drug discovery and biologics manufacturing.

Innovative Technology Use Utilizing advanced tech stacks including Microsoft Azure and CIM Technologies, Salubris Bio is optimizing biologics development and data analytics, creating opportunities for technology collaborations and digital health solutions in biotech R&D.

Market & Regulatory Readiness The company's focus on global development, particularly in China with established partnerships, suggests a readiness to navigate diverse regulatory environments and enter emerging markets, making it a promising partner for expanding biologic therapeutic portfolios.

Salubris Biotherapeutics Tech Stack

Salubris Biotherapeutics uses 8 technology products and services including CIM Technologies, math.js, Google Maps, and more. Explore Salubris Biotherapeutics's tech stack below.

  • CIM Technologies
    Cad & Graphics
  • math.js
    Javascript Libraries
  • Google Maps
    Maps
  • Microsoft Azure
    Platform As A Service
  • PHP
    Programming Languages
  • Google Analytics
    Web Analytics
  • Microsoft ASP.NET
    Web Frameworks
  • easy pie chart
    Web Tools And Plugins

Media & News

Salubris Biotherapeutics's Email Address Formats

Salubris Biotherapeutics uses at least 1 format(s):
Salubris Biotherapeutics Email FormatsExamplePercentage
First.Last@salubrisbio.comJohn.Doe@salubrisbio.com
48%
First_Last@salubrisbio.comJohn_Doe@salubrisbio.com
3%
First.Middle@salubrisbio.comJohn.Michael@salubrisbio.com
1%
First.Last@salubrisbio.comJohn.Doe@salubrisbio.com
48%

Frequently Asked Questions

Where is Salubris Biotherapeutics's headquarters located?

Minus sign iconPlus sign icon
Salubris Biotherapeutics's main headquarters is located at 45 West Watkins Mill Road, Gaithersburg, MD 20878, US. The company has employees across 3 continents, including North AmericaAsiaEurope.

What is Salubris Biotherapeutics's official website and social media links?

Minus sign iconPlus sign icon
Salubris Biotherapeutics's official website is salubrisbio.com and has social profiles on LinkedInCrunchbase.

What is Salubris Biotherapeutics's SIC code NAICS code?

Minus sign iconPlus sign icon
Salubris Biotherapeutics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Salubris Biotherapeutics have currently?

Minus sign iconPlus sign icon
As of October 2025, Salubris Biotherapeutics has approximately 37 employees across 3 continents, including North AmericaAsiaEurope. Key team members include Chief Medical Officer: S. S.Chief Scientific Officer: J. D.Vice President Clinical Operations: A. D.. Explore Salubris Biotherapeutics's employee directory with LeadIQ.

What industry does Salubris Biotherapeutics belong to?

Minus sign iconPlus sign icon
Salubris Biotherapeutics operates in the Biotechnology Research industry.

What technology does Salubris Biotherapeutics use?

Minus sign iconPlus sign icon
Salubris Biotherapeutics's tech stack includes CIM Technologiesmath.jsGoogle MapsMicrosoft AzurePHPGoogle AnalyticsMicrosoft ASP.NETeasy pie chart.

What is Salubris Biotherapeutics's email format?

Minus sign iconPlus sign icon
Salubris Biotherapeutics's email format typically follows the pattern of First.Last@salubrisbio.com. Find more Salubris Biotherapeutics email formats with LeadIQ.

How much funding has Salubris Biotherapeutics raised to date?

Minus sign iconPlus sign icon
As of October 2025, Salubris Biotherapeutics has raised $35M in funding. The last funding round occurred on Apr 22, 2024 for $35M.

When was Salubris Biotherapeutics founded?

Minus sign iconPlus sign icon
Salubris Biotherapeutics was founded in 2016.

Salubris Biotherapeutics

Biotechnology ResearchUnited States11-50 Employees

SalubrisBio was founded in August 2016 as a subsidiary of the China-based pharmaceutical company Salubris Pharmaceuticals Co. Ltd. (www.salubris.com). SalubrisBio is an innovation-focused biotech with pioneering research and development programs. Headquartered in Gaithersburg, Maryland, SalubrisBio represents and reflects Salubris Pharmaceuticals’ commitment to innovation and expansion into the global market. SalubrisBio focuses exclusively on the discovery and global development of novel, biologic therapeutics. 

Salubris Pharmaceuticals is a publicly-traded company [002294:CH], founded in 1998, which has grown to achieve sales of >$750M USD in 2016. Salubris Pharmaceuticals is a fully-integrated drug development company. Headquartered in Shenzhen, China, Salubris Pharmaceuticals has over 3,000 employees working across R&D, regulatory, marketing and sales. Its marketed products include small molecule drugs in the cardiovascular, anti-allergy and anti-infective therapeutic areas. 

GeneKey Biotech Ltd. Co. (www.genekeybio.com), based in Chengdu, China, is the China-based biologics subsidiary of Salubris Pharmaceuticals. GeneKey Biotech has a robust portfolio of biosimilar and novel large molecule therapeutics in development in China. SalubrisBio maintains close cross-functional collaborations with GeneKey Biotech, leveraging resources including the expertise of >150 research scientists and large-scale manufacturing of up to 2000L scale.

Section iconCompany Overview

Headquarters
45 West Watkins Mill Road, Gaithersburg, MD 20878, US
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2016
Employees
11-50

Section iconFunding & Financials

  • $35M

    Salubris Biotherapeutics has raised a total of $35M of funding over 3 rounds. Their latest funding round was raised on Apr 22, 2024 in the amount of $35M.

  • $10M$25M

    Salubris Biotherapeutics's revenue is estimated to be in the range of $10M$25M

Section iconFunding & Financials

  • $35M

    Salubris Biotherapeutics has raised a total of $35M of funding over 3 rounds. Their latest funding round was raised on Apr 22, 2024 in the amount of $35M.

  • $10M$25M

    Salubris Biotherapeutics's revenue is estimated to be in the range of $10M$25M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.